Key summary of German national treatment guidance for hospitalized COVID-19 patients

  1. Malin, Jakob ORCID logo
  2. Spinner, Christoph ORCID logo
  3. Janssens, Uwe ORCID logo
  4. Welte, Tobias ORCID logo
  5. Weber-Carstens, Steffen ORCID logo
  6. Schälte, Gereon ORCID logo
  7. Gastmeier, Petra ORCID logo
  8. Langer, Florian
  9. Wepler, Martin ORCID logo
  10. Westhoff, Michael ORCID logo
  11. Pfeifer, Michael ORCID logo
  12. Rabe, Klaus F. ORCID logo
  13. Hoffmann, Florian ORCID logo
  14. Böttiger, Bernd ORCID logo
  15. Weinmann-Menke, Julia ORCID logo
  16. Kersten, Alexander ORCID logo
  17. Berlit, Peter ORCID logo
  18. Krawczyk, Marcin
  19. Nehls, Wiebke ORCID logo
  20. Fichtner, Falk
  21. Laudi, Sven ORCID logo
  22. Stegemann, Miriam Songa ORCID logo
  23. Skoetz, Nicole ORCID logo
  24. Nothacker, Monika ORCID logo
  25. Marx, Gernot ORCID logo
  26. Karagiannidis, M.D., Pr. Christian ORCID logo
  27. Kluge, Stefan ORCID logo

Download
s15010-021-01645-2.pdf 897,62KB
WeightNameValue
1000 Titel
  • Key summary of German national treatment guidance for hospitalized COVID-19 patients
1000 Autor/in
  1. Malin, Jakob |
  2. Spinner, Christoph |
  3. Janssens, Uwe |
  4. Welte, Tobias |
  5. Weber-Carstens, Steffen |
  6. Schälte, Gereon |
  7. Gastmeier, Petra |
  8. Langer, Florian |
  9. Wepler, Martin |
  10. Westhoff, Michael |
  11. Pfeifer, Michael |
  12. Rabe, Klaus F. |
  13. Hoffmann, Florian |
  14. Böttiger, Bernd |
  15. Weinmann-Menke, Julia |
  16. Kersten, Alexander |
  17. Berlit, Peter |
  18. Krawczyk, Marcin |
  19. Nehls, Wiebke |
  20. Fichtner, Falk |
  21. Laudi, Sven |
  22. Stegemann, Miriam Songa |
  23. Skoetz, Nicole |
  24. Nothacker, Monika |
  25. Marx, Gernot |
  26. Karagiannidis, M.D., Pr. Christian |
  27. Kluge, Stefan |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-07-06
1000 Erschienen in
1000 Quellenangabe
  • 50(1):93-106
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s15010-021-01645-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259552/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!This executive summary of a national living guideline aims to provide rapid evidence based recommendations on the role of drug interventions in the treatment of hospitalized patients with COVID-19.!##!Methods!#!The guideline makes use of a systematic assessment and decision process using an evidence to decision framework (GRADE) as recommended standard WHO (2021). Recommendations are consented by an interdisciplinary panel. Evidence analysis and interpretation is supported by the CEOsys project providing extensive literature searches and living (meta-) analyses. For this executive summary, selected key recommendations on drug therapy are presented including the quality of the evidence and rationale for the level of recommendation.!##!Results!#!The guideline contains 11 key recommendations for COVID-19 drug therapy, eight of which are based on systematic review and/or meta-analysis, while three recommendations represent consensus expert opinion. Based on current evidence, the panel makes strong recommendations for corticosteroids (WHO scale 5-9) and prophylactic anticoagulation (all hospitalized patients with COVID-19) as standard of care. Intensified anticoagulation may be considered for patients with additional risk factors for venous thromboembolisms (VTE) and a low bleeding risk. The IL-6 antagonist tocilizumab may be added in case of high supplemental oxygen requirement and progressive disease (WHO scale 5-6). Treatment with nMABs may be considered for selected inpatients with an early SARS-CoV-2 infection that are not hospitalized for COVID-19. Convalescent plasma, azithromycin, ivermectin or vitamin D!##!Conclusion!#!For COVID-19 drug therapy, there are several options that are sufficiently supported by evidence. The living guidance will be updated as new evidence emerges.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Hospitalization [MeSH]
lokal Humans [MeSH]
lokal Practice Guidelines as Topic [MeSH]
lokal COVID-19
lokal Living guideline
lokal COVID-19/therapy [MeSH]
lokal COVID-19 / SARS-CoV-2
lokal Original Paper
lokal Immunization, Passive [MeSH]
lokal Living meta-analysis
lokal SARS-CoV-2 [MeSH]
lokal SARS-CoV-2
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-2989-0436|https://orcid.org/0000-0002-3875-5367|https://orcid.org/0000-0001-6872-1910|https://orcid.org/0000-0002-9947-7356|https://orcid.org/0000-0001-7405-0172|https://orcid.org/0000-0002-3948-7050|https://orcid.org/0000-0001-5520-4287|https://frl.publisso.de/adhoc/uri/TGFuZ2VyLCBGbG9yaWFu|https://orcid.org/0000-0003-2015-814X|https://orcid.org/0000-0003-2514-1304|https://orcid.org/0000-0003-1983-5000|https://orcid.org/0000-0002-7020-1401|https://orcid.org/0000-0002-2713-2455|https://orcid.org/0000-0001-8000-8931|https://orcid.org/0000-0001-7344-8381|https://orcid.org/0000-0002-4919-7866|https://orcid.org/0000-0002-9544-7256|https://frl.publisso.de/adhoc/uri/S3Jhd2N6eWssIE1hcmNpbg==|https://orcid.org/0000-0001-8078-1182|https://frl.publisso.de/adhoc/uri/RmljaHRuZXIsIEZhbGs=|https://orcid.org/0000-0002-2117-0944|https://orcid.org/0000-0002-7968-0429|https://orcid.org/0000-0003-4744-6192|https://orcid.org/0000-0003-4928-7391|https://orcid.org/0000-0003-0866-4234|https://orcid.org/0000-0003-3247-2849|https://orcid.org/0000-0001-8391-3988
1000 Hinweis
  • DeepGreen-ID: d8ec9327884e4007a3cd226874c62226 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6444036.rdf
1000 Erstellt am 2023-04-27T11:45:29.673+0200
1000 Erstellt von 322
1000 beschreibt frl:6444036
1000 Zuletzt bearbeitet Fri Oct 20 11:53:44 CEST 2023
1000 Objekt bearb. Fri Oct 20 11:53:44 CEST 2023
1000 Vgl. frl:6444036
1000 Oai Id
  1. oai:frl.publisso.de:frl:6444036 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source